Journal September 16, 2026 5 min read

How to Reconstitute Hexarelin

Hexarelin is a growth hormone secretagogue receptor agonist. This page covers its identity, research findings in animal and in vitro models, and the laboratory procedure for reconstitution.

peptides-pro Editorial

How to reconstitute Hexarelin

Hexarelin (also known as examorelin) is a synthetic hexapeptide growth hormone secretagogue and a GHS-R1a agonist. Its sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, with a molecular formula of C47H58N12O6 and a molecular weight of 887.04 g/mol. In the research literature, it is classified as a growth hormone secretagogue (GHS) and is often grouped with other GHRPs such as GHRP-2 and GHRP-6 [3].

The work on hexarelin centres on the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor that mediates ghrelin signalling and is the target through which the peptide exerts its characterised effects in experimental models [1][7].

For laboratory use, hexarelin is typically supplied as a lyophilised powder and must be reconstituted before experimental administration. The standard laboratory procedure is to add a suitable solvent, most commonly bacteriostatic water or sterile saline, to the vial and gently swirl until the powder is fully dissolved. The resulting solution should be clear and particle-free. Because the peptide is sensitive to degradation, reconstituted solutions are generally stored refrigerated and protected from light, and are used within a defined period. The exact volume of solvent depends on the desired working concentration for the experiment; no single concentration is universally applicable.

This page summarises the published research on hexarelin and outlines the reconstitution procedure for laboratory use. It does not provide dosing or medical guidance.

Research Studies

Hexarelin and retinal ganglion cell survival after optic nerve transection

In a study using 8–9 week old golden hamsters, hexarelin was administered after optic nerve transection (ONT) to assess its effect on retinal ganglion cell (RGC) survival. In the single-dose regimen, animals received daily injections of saline, 25 μg/kg, 50 μg/kg, or 100 μg/kg hexarelin for 5 days following ONT. In the two-dose regimen, animals received saline, 100 μg/kg, or 150 μg/kg hexarelin twice daily for 5 days. RGC survival was quantified by immunostaining with Tuj1. The study reported that hexarelin promoted RGC survival after ONT [1].

Hexarelin and apoptosis in ischemic acute kidney injury via MDM2/p53

In a rat model of ischemia/reperfusion (I/R)-induced acute kidney injury (AKI), animals were pretreated with hexarelin at 100 μg/kg/day for 7 days before being sacrificed 24 hours post-IRI. Kidney function, histology, and apoptosis were assessed. The study also included in vitro experiments. The findings indicated that hexarelin alleviated apoptosis in ischemic AKI, with the effect linked to the MDM2/p53 pathway [2].

Hexarelin and the GH-IGF-1 axis

Hexarelin is listed among growth hormone secretagogues (GHS) that modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis. A review of performance-enhancing peptides marketed as research compounds identified hexarelin alongside GHRP-2, GHRP-6, and ipamorelin as agents commonly encountered in clinical practice and online self-administration protocols [3]. This evidence is observational and does not establish efficacy or safety in humans.

Hexarelin and CD36 receptor modulation in a SARS-CoV-2 mouse model

In a study using K18-hACE2 mice infected with SARS-CoV-2, a cluster of differentiation 36 (CD36) receptor modulator was investigated for its effect on the hyper-inflammatory response. The viral infection stimulated alveolar macrophages to adopt an inflammatory phenotype regulated, at least in part, by CD36. Hexarelin was not the primary focus of this study, but the work provides context for CD36-related inflammatory pathways that may intersect with hexarelin research [4].

Hexarelin and intestinal permeation enhancers

All-atom molecular dynamics simulations were used to study the interaction between two permeability enhancers (sodium caprate and SNAC) and four peptides (octreotide, hexarelin, degarelix, and insulin) in the presence of taurocholate, an intestinal bile salt. The enhancers exhibited distinct effects on peptide release based on their properties, promoting hydrophobic peptide release while inhibiting water-soluble peptide release. Lowering peptide concentrations reduced peptide–peptide interactions but increased their interactions with other components. This in vitro work is relevant to oral formulation strategies for peptides such as hexarelin [5].

Hexarelin and MPTP-induced lung injury in mice

A study in male Balb/C mice investigated the protective and therapeutic effects of hexarelin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lung injury. The study evaluated oxidative stress, IL-6-mediated inflammation, and Caspase-3-dependent apoptosis. The findings reported protective and restorative effects of hexarelin in this model [6].

Hexarelin and alexamorelin biomarkers

Alexamorelin is a synthetic peptide and growth hormone secretagogue (GHS) with potential performance-enhancing properties. It mimics the natural peptide hormone ghrelin by binding to the GHS type 1a receptor (GHS-R1a). A study using human hepatocyte incubations and high-resolution mass spectrometry identified consumption biomarkers for alexamorelin. This work is relevant to doping monitoring and does not directly concern hexarelin, but it illustrates the broader context of GHS-R1a agonist research [7].

Reconstitution procedure

Reconstitution is a laboratory step that must be performed with appropriate technique to avoid contamination and degradation. The following general steps apply to hexarelin and similar peptides:

Allow the lyophilised powder and solvent to reach room temperature before opening.
Swab the vial stoppers with an alcohol wipe and allow to dry.
Using a sterile syringe, draw up the desired volume of bacteriostatic water or sterile saline.
Insert the needle into the vial and direct the stream of solvent against the inside wall of the vial, not directly onto the powder, to avoid foaming.
Gently swirl the vial until the powder is completely dissolved. Do not shake vigorously.
Inspect the solution: it should be clear and free of particles. If not, do not use it.
Store the reconstituted solution refrigerated, protected from light, and use within the period recommended by the supplier or established by laboratory protocol.

Note that the optimal solvent, concentration, and storage conditions may vary depending on the specific experimental requirements. Always consult the product data sheet and your institution's guidelines.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.